Key statistics
On Monday, Onconetix Inc (J4T:MUN) closed at 2.60, 20.37% above the 52 week low of 2.16 set on Dec 01, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.00 |
|---|---|
| High | 2.60 |
| Low | 2.60 |
| Bid | -- |
| Offer | -- |
| Previous close | 2.60 |
| Average volume | -- |
|---|---|
| Shares outstanding | 1.56m |
| Free float | 1.25m |
| P/E (TTM) | -- |
| Market cap | 1.85m USD |
| EPS (TTM) | -350.74 USD |
Data delayed at least 15 minutes, as of Dec 01 2025 12:38 GMT.
More ▼
Announcements
- Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
- Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
- Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
- Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
- Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
- Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
- Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
- Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
- Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
- Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
More ▼
